Silverman Henry
University of Maryland School of Medicine, Department of Medicine, 10 S. Pine Street, Suite 800, Baltimore, MD 21201, USA.
Proc Am Thorac Soc. 2007 May;4(2):180-4; discussion 184. doi: 10.1513/pats.200701-010GC.
While the focus of ethical clinical trial conduct has been on protocol review in advance of the research, there has been a recent emphasis on monitoring subject welfare during the conduct of research. The ethical conduct of a clinical trial does not end with the formulation of study design or the obtainment of a signature on the informed consent form. This article defines and describes the necessary monitoring responsibilities to ensure the adequate protection of the rights and welfare of human subjects and the four parties who share such responsibilities: the institutional review board, the data monitoring committee (or the data safety and monitoring board), the sponsor, and the investigator. This article also reviews the numerous challenges associated with monitoring--such as overlapping responsibilities, communication gaps, and lack of standards--and attempts to provide recommendations to address some of these issues.
虽然伦理临床试验行为的重点一直是在研究之前进行方案审查,但最近人们开始强调在研究进行过程中监测受试者的福利。临床试验的伦理行为并不以研究设计的制定或在知情同意书上获得签名而结束。本文定义并描述了必要的监测职责,以确保充分保护人类受试者的权利和福利,以及承担此类责任的四方:机构审查委员会、数据监测委员会(或数据安全监测委员会)、申办者和研究者。本文还审视了与监测相关的众多挑战,如职责重叠、沟通差距和缺乏标准等,并试图就解决其中一些问题提供建议。